+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alzheimer's Disease Drugs Market by Therapy Type, Drug Class, Formulation, Distribution Channel, End User - Global Forecast to 2030- Product Image
Alzheimer's Disease Drugs Market by Therapy Type, Drug Class, Formulation, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Alzheimer's Disease Drugs Market by Therapy Type, Drug Class, Formulation, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4905145
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Alzheimer’s Disease Drugs Market is evolving rapidly, with new therapies reshaping patient care and driving significant industry transformation. Senior leaders must understand the market’s dynamic structure, influential trends, and strategic implications to make informed decisions in this complex and competitive sector.

Market Snapshot: Alzheimer’s Disease Drugs Market

The Alzheimer’s Disease Drugs Market grew from USD 4.74 billion in 2024 to USD 5.22 billion in 2025. It is expected to continue growing at a CAGR of 10.14%, reaching USD 8.46 billion by 2030. This growth reflects accelerated innovation in disease-modifying therapies, evolving reimbursement protocols, and increased healthcare investment globally. The sector is witnessing marked shifts in its regulatory landscape, along with the adoption of advanced biomarkers and diagnostics, shaping the trajectory of both pipeline developments and market approvals.

Scope & Segmentation

  • Therapy Types: Disease-modifying (including monoclonal antibodies and small molecules targeting amyloid beta and tau), symptomatic treatments (such as cholinesterase inhibitors, NMDA receptor antagonists).
  • Drug Classes: Cholinesterase inhibitors, monoclonal antibodies (amyloid beta antibodies, tau protein antibodies), NMDA receptor antagonists.
  • Formulation Approaches: Injectable (intravenous infusions, subcutaneous injections), and oral (capsules, tablets).
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • End Users: Clinics, homecare, hospitals, and referral hubs.
  • Regional Coverage: Americas (including US, Canada, Brazil, Mexico, Argentina), Europe, Middle East & Africa (notably UK, Germany, France, Saudi Arabia, South Africa), Asia-Pacific (including Japan, China, India, Australia, South Korea, Singapore).
  • Leading Companies: Eisai Co., Ltd.; AbbVie Inc.; Novartis AG; Johnson & Johnson; Biogen Inc.; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; Viatris Inc.; Apotex Inc.

Key Takeaways

  • Next-generation monoclonal antibody therapies are driving a significant shift towards disease modification in Alzheimer’s treatment paradigms.
  • Emerging small molecule agents focus on addressing underlying neuroinflammatory pathways and synaptic health, reflecting a multi-mechanistic approach.
  • Technological advances in digital health platforms and diagnostic biomarkers enhance early detection, patient stratification, and ongoing remote monitoring.
  • Evolving payer models, including outcomes-based pricing, are aligning reimbursement schemes with demonstrated patient response and long-term cost efficiency.
  • Cross-sector collaborations among pharmaceutical leaders and biotechnology innovators are strengthening platforms, accelerating regulatory milestones, and expanding global reach.
  • Segment analysis shows symptomatic therapies remain important for cognitive and behavioral symptom management, especially in outpatient and community care environments.

Tariff Impact: US Pharmaceutical Supply Chains

Revised United States tariffs on pharmaceutical imports, effective from 2025, are introducing cost pressures across the Alzheimer’s drug supply chain. Elevated duties on active pharmaceutical ingredients and finished drugs sourced from key production regions are increasing operational costs and influencing pricing negotiations. Pharmaceutical companies are responding by diversifying their supply bases and exploring domestic manufacturing options. Real-time analytics support stakeholders in inventory allocation and scenario planning as they adjust to new tariff-influenced cost structures. Pricing strategies and contracting models are evolving to preserve affordable patient access despite heightened market volatility.

Methodology & Data Sources

This research integrates qualitative and quantitative analysis drawing from peer-reviewed literature, regulatory filings, patent landscapes, and proprietary databases. Input from key opinion leaders, clinical researchers, and payer representatives enriches market trend assessments. All findings are cross-validated with subject matter experts to ensure data robustness and relevance for strategic planning.

Why This Report Matters

  • Provides clarity on emerging therapy classes, regulatory shifts, and technology adoption impacting Alzheimer’s drug development.
  • Supports supply chain, pricing, and investment decisions with actionable market segmentation and regional dynamics analysis.
  • Equips senior leaders and stakeholders with frameworks for opportunity identification, risk mitigation, and competitive strategy alignment in the evolving Alzheimer’s Disease Drugs Market.

Conclusion

The Alzheimer’s Disease Drugs Market is at a pivotal stage, advancing through scientific innovation, operational adaptation, and shifting payer requirements. Organizations positioned for agility and collaboration stand to benefit most from these evolving opportunities and challenges.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Alzheimer's Disease Drugs Market, by Therapy Type
8.1. Introduction
8.2. Disease Modifying
8.2.1. Monoclonal Antibodies
8.2.1.1. Amyloid Beta Antibodies
8.2.1.2. Tau Protein Antibodies
8.3. Symptomatic
8.3.1. Cholinesterase Inhibitors
8.3.2. Nmda Receptor Antagonists
9. Alzheimer's Disease Drugs Market, by Drug Class
9.1. Introduction
9.2. Cholinesterase Inhibitors
9.3. Monoclonal Antibodies
9.3.1. Amyloid Beta Antibodies
9.3.2. Tau Protein Antibodies
9.4. Nmda Receptor Antagonists
10. Alzheimer's Disease Drugs Market, by Formulation
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous Infusion
10.2.2. Subcutaneous Injection
10.3. Oral
10.3.1. Capsule
10.3.2. Tablet
11. Alzheimer's Disease Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Alzheimer's Disease Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare
12.4. Hospitals
13. Americas Alzheimer's Disease Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Alzheimer's Disease Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Alzheimer's Disease Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eisai Co., Ltd.
16.3.2. AbbVie Inc.
16.3.3. Novartis AG
16.3.4. Johnson & Johnson
16.3.5. Biogen Inc.
16.3.6. Eli Lilly and Company
16.3.7. Teva Pharmaceutical Industries Ltd.
16.3.8. Sandoz International GmbH
16.3.9. Viatris Inc.
16.3.10. Apotex Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ALZHEIMER'S DISEASE DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ALZHEIMER'S DISEASE DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ALZHEIMER'S DISEASE DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ALZHEIMER'S DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ALZHEIMER'S DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ALZHEIMER'S DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY TAU PROTEIN ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY AMYLOID BETA ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY TAU PROTEIN ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 67. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 68. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 69. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 71. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 72. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 73. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 74. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 133. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 134. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 135. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 136. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 138. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 139. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 140. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 141. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 144. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 145. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 147. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 166. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 167. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 169. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 171. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 172. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 173. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 174. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 177. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 178. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 179. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 180. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 182. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 183. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 184. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 185. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 221. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 222. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 223. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 224. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 226. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 227. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 228. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 229. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 243. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 244. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 245. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 246. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 248. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 249. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 250. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 251. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 254. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 255. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 256. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 257. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 259. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 260. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 261. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 262. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 265. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 277. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 287. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 288. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 289. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 290. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 292. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 293. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 294. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 295. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 298. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 299. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 300. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 301. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 303. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 304. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 305. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 306. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY SYMPTOMATIC, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. NORWAY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 320. NORWAY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISEASE MODIFYING, 2018-2030 (USD MILLION)
TABLE 321. NORWAY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MONOCLONAL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Alzheimer's Disease Drugs market report include:
  • Eisai Co., Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Biogen Inc.
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Apotex Inc.

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.22 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.46 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Agitation in Alzheimer's Disease Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035 - Product Image

Agitation in Alzheimer's Disease Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Alzheimer's Disease Diagnostics & Therapeutics Market by Product, Drug Class, Patient Demographics, Disease Stage, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Alzheimer's Disease Diagnostics & Therapeutics Market by Product, Drug Class, Patient Demographics, Disease Stage, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Alzheimer's Drugs - A Global Market Overview - Product Image

Alzheimer's Drugs - A Global Market Overview

  • Report
  • 253 Pages
  • Global
From
Alzheimer's Disease Drugs - Global Strategic Business Report - Product Image

Alzheimer's Disease Drugs - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Alzheimer's Disease - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Alzheimer's Disease - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Alzheimer's Disease Drugs Market

The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone. The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.